However, an increase in IL-17A expression has been shown in the advanced stages of HBV-related liver disease by the immunohistochemistry on fresh biopsies of HBV+ patients (12, 15, 105–107) or patients with non-alcoholic steatohepatitis (99). Here, IL17A is linked to metabolic dysfunction-associated steatohepatitis.